Abstract:To compare the treatment outcomes of breast conserving surgery plus radiotherapy (BCS+RT) vs. mastectomy plus radiotherapy (mastectomy+RT) vs. mastectomy without radiotherapy (mastectomy alone) for patients with pT1-2N1 triple negative breast cancer (TNBC). A total of 412 patients with pT1-2N1 TNBC treated between 1999 and 2013 were analyzed. Patients underwent BCS+RT (n=48) or mastectomy+RT (n=103) or mastectomy alone (n=261). No neoadjuvant chemotherapy was used and axillary dissection was performed for all patients. All received adjuvant chemotherapy, mainly anthrathycline- and/or taxane-based regimens. The Locoregional recurrence (LRR), disease-free survival (DFS) and overall survival (OS) rates were calculated by the Kaplan-Meier method and compared with log-rank test. Multivariate analysis was performed by Cox model. The median follow-up time was 61 months.The median age was 49 years (range, 21-82). The median nubmer of positive axillary nodes was 1 (range, 1-3) and the median number of nodes dissected was 19. BCT+RT group and mastectomy+RT group had more patients with age < 50 years than mastectomy alone group (68.8% vs. 63.1% vs. 46.0%, p < 0.001). mastectomy+RT group had more patients with 2-3 positive nodes than BCT+RT group and mastectomy alone group (63.1% vs. 41.7% vs. 41.4%, p = 0.001). BCT+RT group had more T1 tumors than mastectomy+RT group and mastectomy alone group (64.5% vs. 31.1% vs. 44.4%, p < 0.001). mastectomy+RT group had more T2 tumors than mastectomy alone group (68.9% vs. 55.6%, p = 0.019). Among BCT+RT group, mastectomy+RT group and mastectomy alone group, the 5-year LRR rates were 2.4% vs. 6.2% vs. 12.8% (p=0.180), the 5-year DFS rates were 90.4% vs. 85.7% vs. 72.7% (p=0.038), the 5-year OS rates were 91.6% vs. 89.4% vs. 85.6% (p=0.098). There were no significant differences in DFS and OS between BCT+RT group and mastectomy+RT group (p=0.267, p=0.814), however mastectomy only group had lower DFS and OS than matectomy+RT group (p=0.034, p=0.082). Multivariate analysis showed similar results after adjusting for covariates: there were no significant differences in LRR, DFS and OS between BCT+RT group and mastectomy+RT group; mastectomy alone was independently associated with higher LRR (p=0.008, HR:2.86) and lower DFS and OS (p=0.002, HR:2.08; and p=0.009, HR:2.35) as compared with BCT or mastectomy plus RT. T2 tumors was independent unfavorable prognostic factor for LRR, DFS and OS (p=0.026, p=0.002, p=0.010, respectively). In addition, age < 50 years (p=0.017) and 2-3 positive nodes (p=0.019) were independent unfavorable prognostic factor for LRR. In pT1-2N1 TNBC, breast conserving surgery plus RT achieved comparable outcomes with mastectomy plus RT, but mastectomy without RT had poorer outcomes. This indicates that breast conserving therapy is safe and postmastecomy RT is recommended for all patients.

Locoregional and Distant Recurrences after Breast Conserving Therapy in Patients with Triple-Negative Breast Cancer: A Meta-Analysis

A Bayesian network meta-analysis of the efficacy of targeted therapies and chemotherapy for treatment of triple-negative breast cancer.

Breast-Conserving Therapy Achieves Locoregional Outcomes Comparable to Mastectomy in Women with T1-2N0 Triple-Negative Breast Cancer

[Safety of Breast-Conserving Treatment for Triple-Negative Breast Cancer].

Breast-conserving therapy for breast cancer with BRCA mutations: a meta-analysis

Breast Conservation Therapy Achieved Comparable Outcomes With Mastectomy In Patients With T1-2n0 Triple-Negative Breast Cancer: Analysis Of 822 Patients In A Single Institution

Mastectomy Without Radiation Therapy Had Inferior Outcomes As Compared To Breast Conserving Surgery Or Mastectomy Plus Radiation Therapy In Patients With T1-2n1 Triple-Negative Breast Cancer: Analysis Of 412 Patients In A Single Institution

Local treatment for triple-negative breast cancer patients undergoing chemotherapy: breast-conserving surgery or total mastectomy?

Influence of Radiation Therapy on the Outcome of T1-2N0M0 Triple-Negative Breast Cancer: A SEER Population-Based Retrospective Analysis.

Predicting Locoregional Recurrence in Triple-Negative Breast Cancer Using Novel Molecular Subtyping.

Locoregional Recurrence by Tumor Biology in Breast Cancer Patients after Preoperative Chemotherapy and Breast Conservation Treatment

Improved locoregional control with conventional radiotherapy following modified radical mastectomy for patients with T1-2N1M0 triple-negative breast cancer

Radiotherapy Can Improve The Disease-Free Survival Rate In Triple-Negative Breast Cancer Patients With T1-T2 Disease And One To Three Positive Lymph Nodes After Mastectomy

Breast-Conserving Therapy Has Better Prognosis for Tumors in the Central and Nipple Portion of Breast Cancer Compared with Mastectomy: A SEER Data-Based Study

Postmastectomy radiotherapy reduces locoregional and disease recurrence in patients with stage II-III triple-negative breast cancer treated with neoadjuvant chemotherapy and mastectomy.

Analysis In Early Stage Triple-Negative Breast Cancer Treated With Mastectomy Without Adjuvant Radiotherapy: Patterns Of Failure And Prognostic Factors

Radiotherapy May Play an Important Role in Improving the Efficacy of Breast-Conserving Therapy Compared with Mastectomy in Patients with T1-2N1M0 Breast Cancer

Breast-conserving surgery is not associated with increased local recurrence in patients with early-stage node-negative triple-negative breast cancer treated with neoadjuvant chemotherapy

Biological subtype predicts locoregional recurrence after postmastectomy radiotherapy in Chinese breast cancer patients.

Breast-conserving Therapy and Modified Radical Mastectomy for Primary Breast Carcinoma: a Matched Comparative Study.

Postmastectomy Radiation Therapy Reduces Locoregional Recurrence and Disease Recurrence in Triple-Negative Breast Cancer Patients with Stage Ii-Iii Treated with Neoadjuvant Chemotherapy and Mastectomy